Mutant IDH1: An immunotherapeutic target in tumors

Abstract

The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mutation-specific CD4⁺ antitumor T cell response in patients and a syngeneic tumor model in MHC-humanized mice.